Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.03. | NSE - LumiraDx Ltd - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 5 | SEC Filings | ||
20.03. | Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival ... | 104 | GlobeNewswire (Europe) | NEW YORK" March 20, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of Latch, Inc. Latch, Inc.'s securities were suspended on August... ► Artikel lesen | |
06.02. | LumiraDx Ltd - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
08.01. | Why Is LumiraDx (LMDX) Stock Down 13% Today? | 11 | InvestorPlace | ||
08.01. | Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket | 4 | Benzinga.com | ||
06.01. | LumiraDx to be delisted from Nasdaq on January 9 | 4 | Investing.com | ||
05.01. | LumiraDx says its securities will be suspended from trading on Nasdaq | 2 | Seeking Alpha | ||
05.01. | LumiraDx Inc: LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th | 280 | GlobeNewswire (Europe) | LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities... ► Artikel lesen | |
02.01. | Roche to pick up LumiraDx's point-of-care tests through $350M deal | 19 | FierceBiotech | ||
02.01. | Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology | 12 | Zacks | ||
02.01. | Why LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket | 3 | Benzinga.com | ||
02.01. | Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M | 11 | Benzinga.com | ||
02.01. | LumiraDx falls on agreement with Roche to sell assets | 15 | Seeking Alpha | ||
02.01. | BioPharma Credit to fund LumiraDx ahead of acquisition by Roche | 13 | Alliance News | ||
02.01. | LumiraDx, Sacks Parente Golf And 3 Stocks To Watch Heading Into Tuesday | 2 | Benzinga.com | ||
01.01. | Roche bolsters diagnostics with $295m LumiraDx deal | 12 | pharmaphorum | ||
31.12.23 | Roche to acquire LumiraDx's Point of Care technology for $295 million plus up to $55 million | 7 | POST Online Media | ||
30.12.23 | Roche to buy part of LumiraDx diagnostics platform for $295 million | 21 | Reuters | ||
29.12.23 | LumiraDx Agrees To Sell Point-of-Care Tech Platform To Roche | 6 | RTTNews | ||
29.12.23 | F. Hoffmann-La Roche Ltd: Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform | 777 | GlobeNewswire (Europe) | The transformative point of care solution will complement Roche's centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ORPEA | 12,500 | -1,34 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 3,150 | -1,32 % | Tempest Therapeutics: Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications | TPST-1120, a first-in-class, oral, selective PPAR? antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data... ► Artikel lesen | |
NANO-X IMAGING | 9,290 | 0,00 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
BUTTERFLY NETWORK | 0,740 | 0,00 % | ThinkSono Ltd: ThinkSono Releases Real-Time DVT AI Training Solution for Butterfly Network's Handheld Ultrasound Devices | LONDON, ENGLAND / ACCESSWIRE / April 23, 2024 / ThinkSono, a pioneering provider of AI-driven medical imaging solutions, is proud to announce the release of ThinkSono AI Training, a deep vein thrombosis... ► Artikel lesen | |
INTELLIGENT BIO SOLUTIONS | 3,870 | -100,00 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results | NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
GOODRX | 6,970 | +4,65 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
JOINT CORP | 12,610 | +2,02 % | The Joint Corp. to Host Conference Call on Thursday, May 2nd to Discuss First Quarter 2024 Results | ||
CARMAT | 3,800 | +0,26 % | CARMAT Announces Its 2023 Annual Results and Provides an Update on Its Progress and Prospects for 2024 | 2023 sales of €2.8 million, i.e. 17 Aeson® implants, including 11 in the last quarter
2024 sales forecast of around €14 million
Active exploration of financing options to extend... ► Artikel lesen | |
HYPERFINE | 0,810 | 0,00 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
PROGYNY | 32,370 | 0,00 % | Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care | ||
BIOMERICA | 0,720 | -0,65 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
MIMEDX | 6,500 | +2,20 % | MiMedx Group, Inc: MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results | Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter... ► Artikel lesen | |
ATRICURE | 23,150 | +1,94 % | AtriCure upgraded at Oppenheimer on valuation | ||
ATRION | 376,00 | +0,53 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
CASTLE BIOSCIENCES | 20,035 | +2,17 % | Castle Biosciences Inc.: Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC Tests on the Management of Patients with Skin Cancer | If choosing to use a molecular test to rule-out a sentinel lymph node biopsy (SLNB) in patients diagnosed with melanoma, it is important to show that patients foregoing an SLNB have low risk outcomes... ► Artikel lesen |